Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene–related peptide inhibitors vs other preventive migraine treatments in the United States

BACKGROUND: Limited data are available on health care resource utilization (HCRU) and health care costs of calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) for preventive treatment of migraine. OBJECTIVE: To compare all-cause and migraine-related HCRU and direct health care costs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnado, Oralee J, Manjelievskaia, Janna, Ye, Wenyu, Perry, Allison, Schuh, Kory, Wenzel, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373045/
https://www.ncbi.nlm.nih.gov/pubmed/35876297
http://dx.doi.org/10.18553/jmcp.2022.28.8.818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373045/
https://www.ncbi.nlm.nih.gov/pubmed/35876297
http://dx.doi.org/10.18553/jmcp.2022.28.8.818

Ejemplares similares